Warfarin dosing test
This article was originally published in The Gray Sheet
Executive Summary
Kimball Genetics joins the small number of labs performing pharmacogenetic tests for warfarin therapy with the launch of its Warfarin DoseAdvise June 5. The test, performed at Kimball's CLIA-certified lab in Denver, analyzes genes in blood or cheek cell samples to inform dosing of the common blood thinner. According to Kimball CEO Annette Taylor, FDA plans to revise warfarin product labeling to advocate genetic testing. Other labs offering warfarin dosing tests include Clinical Data (PGxPredict). Third Wave, which sells reagents for warfarin tests, is developing the Invader warfarin in vitro diagnostic (1"The Gray Sheet" March 6, 2006, p. 12)...
You may also be interested in...
Third Wave, Now An IVD Company, Is Banking On Personalized Medicine
Third Wave Technologies is banking on its emerging portfolio of in vitro diagnostic products designed to tailor drug therapy to recover from substantial revenue losses in its research products business
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: